BR112022016232A2 - Proteínas biespecíficas anti-her2 manipuladas - Google Patents
Proteínas biespecíficas anti-her2 manipuladasInfo
- Publication number
- BR112022016232A2 BR112022016232A2 BR112022016232A BR112022016232A BR112022016232A2 BR 112022016232 A2 BR112022016232 A2 BR 112022016232A2 BR 112022016232 A BR112022016232 A BR 112022016232A BR 112022016232 A BR112022016232 A BR 112022016232A BR 112022016232 A2 BR112022016232 A2 BR 112022016232A2
- Authority
- BR
- Brazil
- Prior art keywords
- manipulated
- subdomain
- bispecific anti
- her2
- proteins
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062978758P | 2020-02-19 | 2020-02-19 | |
| PCT/US2021/018705 WO2021168194A1 (en) | 2020-02-19 | 2021-02-19 | Engineered anti-her2 bispecific proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022016232A2 true BR112022016232A2 (pt) | 2022-11-16 |
Family
ID=77391704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022016232A BR112022016232A2 (pt) | 2020-02-19 | 2021-02-19 | Proteínas biespecíficas anti-her2 manipuladas |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230192887A1 (https=) |
| EP (1) | EP4181950A4 (https=) |
| JP (1) | JP2023514371A (https=) |
| KR (1) | KR20220156526A (https=) |
| CN (1) | CN115361972A (https=) |
| AR (1) | AR121384A1 (https=) |
| AU (1) | AU2021224200A1 (https=) |
| BR (1) | BR112022016232A2 (https=) |
| CA (1) | CA3170338A1 (https=) |
| IL (1) | IL295729A (https=) |
| MX (1) | MX2022010161A (https=) |
| TW (1) | TW202144431A (https=) |
| WO (1) | WO2021168194A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110506055A (zh) | 2017-02-17 | 2019-11-26 | 戴纳立制药公司 | 工程改造的转铁蛋白受体结合多肽 |
| BR112021015656A2 (pt) | 2019-02-20 | 2021-10-05 | Denali Therapeutics Inc. | Anticorpos anti-trem2 e métodos de uso dos mesmos |
| EP4229192A1 (en) | 2020-10-14 | 2023-08-23 | Denali Therapeutics Inc. | Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof |
| WO2023038803A2 (en) * | 2021-08-25 | 2023-03-16 | Denali Therapeutics Inc. | Engineered anti-her2 bispecific proteins |
| MA71684A (fr) * | 2022-08-05 | 2025-05-30 | Janssen Biotech, Inc. | Protéines de liaison de récepteur de transferrine pour traitement de tumeurs cérébrales |
| CA3263779A1 (en) * | 2022-08-05 | 2024-02-08 | Janssen Biotech, Inc. | CD98 LINKAGE CONSTRUCTIONS FOR THE TREATMENT OF BRAIN TUMORS |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005047327A2 (en) * | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| US9101674B2 (en) * | 2010-03-29 | 2015-08-11 | Vib Vzw | Targeting and in vivo imaging of tumor-associated macrophages |
| AU2014357292B2 (en) * | 2013-11-27 | 2020-06-25 | Zymeworks Bc Inc. | Bispecific antigen-binding constructs targeting HER2 |
| WO2015095412A1 (en) * | 2013-12-19 | 2015-06-25 | Zhong Wang | Bispecific antibody with two single-domain antigen-binding fragments |
| EP3083696B1 (en) * | 2013-12-20 | 2018-02-14 | F.Hoffmann-La Roche Ag | Bispecific her2 antibodies and methods of use |
| SG11201608192SA (en) * | 2014-04-11 | 2016-10-28 | Medimmune Llc | Bispecific her2 antibodies |
| CA3138083A1 (en) * | 2014-12-22 | 2016-06-30 | Systimmune, Inc. | Bispecific tetravalent antibodies and methods of making and using thereof |
| CN107531788B (zh) * | 2015-06-24 | 2022-06-21 | 豪夫迈·罗氏有限公司 | 对her2和血脑屏障受体特异性的三特异性抗体及使用方法 |
| US10457717B2 (en) * | 2017-02-17 | 2019-10-29 | Denali Therapeutics Inc. | Engineered polypeptides |
| EP3665194A4 (en) * | 2017-08-10 | 2021-07-07 | Denali Therapeutics Inc. | AFFINITY BASED METHODS OF USING TRANSFERRIN RECEPTOR BINDING PROTEINS |
| JP2021534220A (ja) * | 2018-08-22 | 2021-12-09 | デナリ セラピューティクス インコーポレイテッドDenali Therapeutics Inc. | 抗ｈｅｒ２ポリペプチド及びそれらの使用の方法 |
-
2021
- 2021-02-19 AU AU2021224200A patent/AU2021224200A1/en not_active Abandoned
- 2021-02-19 BR BR112022016232A patent/BR112022016232A2/pt unknown
- 2021-02-19 EP EP21756590.2A patent/EP4181950A4/en active Pending
- 2021-02-19 IL IL295729A patent/IL295729A/en unknown
- 2021-02-19 KR KR1020227028989A patent/KR20220156526A/ko active Pending
- 2021-02-19 AR ARP210100440A patent/AR121384A1/es unknown
- 2021-02-19 TW TW110105842A patent/TW202144431A/zh unknown
- 2021-02-19 MX MX2022010161A patent/MX2022010161A/es unknown
- 2021-02-19 WO PCT/US2021/018705 patent/WO2021168194A1/en not_active Ceased
- 2021-02-19 CN CN202180027050.7A patent/CN115361972A/zh active Pending
- 2021-02-19 JP JP2022549653A patent/JP2023514371A/ja active Pending
- 2021-02-19 CA CA3170338A patent/CA3170338A1/en active Pending
-
2022
- 2022-08-11 US US17/819,182 patent/US20230192887A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230192887A1 (en) | 2023-06-22 |
| AU2021224200A1 (en) | 2022-09-08 |
| AR121384A1 (es) | 2022-06-01 |
| EP4181950A1 (en) | 2023-05-24 |
| MX2022010161A (es) | 2022-11-07 |
| WO2021168194A1 (en) | 2021-08-26 |
| KR20220156526A (ko) | 2022-11-25 |
| CN115361972A (zh) | 2022-11-18 |
| JP2023514371A (ja) | 2023-04-05 |
| EP4181950A4 (en) | 2024-07-17 |
| IL295729A (en) | 2022-10-01 |
| TW202144431A (zh) | 2021-12-01 |
| CA3170338A1 (en) | 2021-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022016232A2 (pt) | Proteínas biespecíficas anti-her2 manipuladas | |
| NZ790656A (en) | Antibodies and fusion proteins that bind to ccr8 and uses thereof | |
| ZA202005259B (en) | Anti-ctla4 antibodies and methods of making and using the same | |
| EA201990781A9 (ru) | Анти-steap2 антитела, конъюгаты антитело-лекарственное средство и биспецифические антигенсвязывающие молекулы, которые связывают steap2 и cd3, и их применение | |
| MX2023005375A (es) | Anticuerpos trivalentes biespecificos unidos a claudina 6 o claudina 18.2 y cd3 para el tratamiento de enfermedades de cancer que expresan claudina. | |
| MX2020008336A (es) | Dominios variables de anticuerpos que se dirigen al receptor nkg2d. | |
| EA201891084A1 (ru) | Антитела к il1rap, биспецифические антигенсвязывающие молекулы, которые связываются с il1rap и cd3, и их применение | |
| BR112021008060A2 (pt) | Polipeptídeo, anticorpo anti-ctla4 ou fragmento de anticorpo, imunoconjugado, composição farmacêutica, dose única de composição farmacêutica, método de tratar câncer, e, kit para diagnóstico ou tratamento | |
| DOP2012000240A (es) | Proteínas terapéuticas de unión a dll4 | |
| EA201990346A1 (ru) | Антитела к gprc5d, биспецифические антигенсвязывающие молекулы, которые связывают gprc5d и cd3, и их применение | |
| CO2019003951A2 (es) | Proteínas de unión a cd123 y composiciones y métodos relacionados | |
| BR112019000436A2 (pt) | anticorpos anti-pd-1, método de produção e método de uso dos mesmos | |
| EA201791393A3 (ru) | Антитела к erbb3 и их применение | |
| CO2021011944A2 (es) | Anticuerpos de cd33 y métodos para usar los mismos para tratar el cáncer | |
| NZ594682A (en) | Fully human antibodies specific to cadm1 | |
| CL2024001384A1 (es) | Moleculas de anticuerpo y conjugados | |
| EA201791691A1 (ru) | ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d | |
| MA43717B1 (fr) | Anticorps anti-tnf alpha et fragments fonctionnels de ceux-ci | |
| BR112021018632A2 (pt) | Moléculas de ligação ao cd3 | |
| PH12021553197A1 (en) | Anti-cd47 antibodies and uses thereof | |
| BR112022021065A2 (pt) | Anticorpos terapêuticos de musk | |
| MX2022009815A (es) | Moleculas de union biespecificas. | |
| CR20230245A (es) | Moléculas de unión a gucy2c y sus usos | |
| MX2025001591A (es) | Proteinas de union a nkg2d, cd16 y ceacam5 | |
| MX2024002408A (es) | Moléculas de unión al antígeno y usos de estas. |